Stage III Prostate Cancer AJCC v8 Clinical Trial
Official title:
Watchful Living: A Lifestyle Intervention for Black and Hispanic Prostate Cancer Patients and Their Partners
Verified date | February 2024 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot trial studies how well Watchful Living works in improving quality of life in participants with prostate cancer that has not spread to other parts of the body who are on active surveillance and their partners. A social support lifestyle intervention (called Watchful Living) may help African American prostate cancer participants and their partners improve their quality of life, physical activity, diet, and inflammation.
Status | Active, not recruiting |
Enrollment | 64 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Self-identify as black or African American or Hispanic (patient) - Be greater than 18 years of age (patient and spouse or intimate partner) - Have 0-III stage prostate cancer (patient) - If treated, have completed therapy (e.g., surgery, chemo and/or radiation) (patient) - Enroll with a spouse or intimate partner (patient) - Do not meet physical activity recommendation (i.e., 150 minutes of moderate intensity physical activity per week) (patient and spouse or intimate partner) - Be ready and able to be physically active, as determined by a physician (letter from a physician or nurse practitioner) (patient and spouse or intimate partner) - Not participate in another physical activity, diet, or lifestyle program (patient) - Have a valid home address and telephone number (patient) - Internet access at home or other location (e.g., work, church, library, community center, etc.) (spouse or intimate partner) - Patients on active surveillance will be included Exclusion Criteria: - They have an active noncutaneous malignancy at any site (patient) - Had prior radiation therapy for treatment of the primary tumor (patient) - Have planned concomitant immunotherapy, hormonal therapy, chemotherapy, or radiation therapy during the study period (patient) - Are enrolled in another active surveillance protocol (patient) - Participated in formative focus groups for this study (patient and spouse or intimate partner) |
Country | Name | City | State |
---|---|---|---|
United States | Harris Health System (LBJ) | Houston | Texas |
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment and retention | Rates of study eligibility, recruitment, and retention will be assessed. Will maintain detailed information during the recruitment process regarding numbers of patients and their partners interested, eligible, ineligible (and reasons for ineligibility), and enrolled (and reasons for choosing not to enroll if deemed eligible). Will calculate rates of study eligibility, recruitment, and retention, along with 90% confidence intervals (CIs). Participant feedback will be summarized using means and standard deviations (SDs), along with graphical display (e.g., box plots). Will also assess reasons for withdrawal from study among those that chose to withdraw. Will examine the differences between dropout and non-dropout group at each time point by demographic factors such as age, gender, marital status, education, and income. | Up to 8 months | |
Primary | Intervention adherence | The intervention adherence rate for each dyad is defined as the proportion of intervention sessions completed by both the patient and partner. Will also look at percentage of both patient and partner completing a minimum of 7 out of 10 coaching calls and both nutrition counseling sessions. | Up to 8 months | |
Secondary | Surveillance lifestyle | Will report means, standard deviations, and distributions of survey measures (including pre-post changes of these measures, as appropriate) for ceiling/floor effects and restrictions in range. Outcome measures will be treated as continuous variables. Linear mixed models will be used when combined data from both patients and partners are analyzed due to their correlation within couples. Two-sided statistical tests will be performed, and the significance level for each test will be set at 0.05 without adjustment for multiple testing. All results from the statistical tests will be interpreted as hypothesis generating rather than conclusive findings. Will also perform paired t-tests to compare efficacy outcomes of interest between baseline and post intervention separately for patients and partners. | Up to 8 months | |
Secondary | Elements of the intervention that were successful and/or need improvements | Will conduct focus groups with a subsample of patient-partner dyads. Questions will address participants' experiences; thoughts about strengths, weaknesses, and needed improvements; perceptions about outcomes and impact; and overall reactions to and satisfaction with the intervention. | Up to 8 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03218826 -
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Recruiting |
NCT04981834 -
Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer
|
N/A | |
Completed |
NCT04976257 -
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
|
Early Phase 1 | |
Recruiting |
NCT06173362 -
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
|
Phase 2 | |
Suspended |
NCT03899987 -
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
|
Phase 2 | |
Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
Not yet recruiting |
NCT06129851 -
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05487846 -
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
|
N/A | |
Recruiting |
NCT05946213 -
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03570827 -
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
|
Phase 2 | |
Recruiting |
NCT03987386 -
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
|
Phase 3 | |
Not yet recruiting |
NCT06325046 -
Evaluating Changes in Quality of Life After Near Margin-less Adaptive Radiation Therapy Compared to Standard Stereotactic Ablative Body Radiotherapy in Localized Prostate Cancer
|
N/A | |
Recruiting |
NCT04134260 -
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
|
Phase 3 | |
Completed |
NCT03177460 -
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05320406 -
RElugolix VErsus LeUprolide Cardiac Trial
|
Phase 4 | |
Completed |
NCT04067960 -
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
|
Early Phase 1 | |
Suspended |
NCT04037254 -
Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05869682 -
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
|
Phase 2 | |
Recruiting |
NCT06389786 -
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
|
N/A | |
Recruiting |
NCT05877144 -
Low-Intensity Shockwave Therapy to Treat Erectile Dysfunction and Preserve Erectile Function After Prostate Cancer Surgery
|
N/A |